The group aberrant antigen AL was seen in 22 cases (12.6%) (included AML-Lym T+: 6 cases, AML-Lym B+: 3 cases and 1 AML - LymB+LymT+ case (CD34+: 70% and CD10 (-): 100%; the most aberrant antigen was CD5+ and CD19+: 40%, the next was CD7+: 20% and the last was CD2+: 10%); B-ALL Myeloid+: 5 cases, B-ALL Lympho T+: 2 cases (CD34+: 85.8%, CD10+: 57.2%; the most aberrant antigen was: CD13+: 42.8%, the next was CD5+: 28.6%, the last were CD15+ and CD33+: 14.3%); T-ALL - Myeloid+: 5 cases (CD34+: 80%; CD10 (-): 100%; the most aberrant antigen was: CD33+: 60%, the next were CD15+ and CD13+: 20%.